Exon-level <i>TP53</i> alterations and PD-L1 expression identified by pretreatment NGS stratify survival in <i>EGFR</i>-mutant non-small cell lung cancer treated with first-line osimertinib.

Transl Lung Cancer Res · 2025 · PMC12775692 · PMID 41510380

Europe PMC DOI

hedged sentence

0.1700

closest p · 3.4× alpha

0.1700

boldest claim

The sentences

a numerical trendP=0.17not close (p > 0.1)

A comparison was performed between the patients with the exon 19 deletion and those with the L858R mutation and identified a numerical trend that favored the exon 19 deletion compared with the L858R mutation in the TTD and OS {TTD: HR =2.31 [95% confidence interval (CI): 0.69–7.70]; P=0.17; OS: HR =2.39 (95% CI: 0.72–7.94); P=0.16} ( Figure S2A,S2B ).

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Exon-level &lt;i&gt;TP53&lt;/i&gt; alterations and PD-L1 expression identified by pretreatment NGS stratify survival in &lt;i&gt;EGFR&lt;/i&gt;-mutant non-small cell lung cancer treated with first-line osimertinib.

The sentences

Exon-level <i>TP53</i> alterations and PD-L1 expression identified by pretreatment NGS stratify survival in <i>EGFR</i>-mutant non-small cell lung cancer treated with first-line osimertinib.